Sugi Predict

Sugi Predict / Targets / TNFRSF9

TNFRSF9

Tumor necrosis factor receptor superfamily member 9 · Q07011 · TNFRSF9 on Sugi Atlas →

188 patent compounds predicted against TNFRSF9, 125 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL20013471 SCHEMBL20013471 0.47 4/20
SCHEMBL20013147 SCHEMBL20013147 0.44 4/20
SCHEMBL22199641 SCHEMBL22199641 0.43 4/20
SCHEMBL20009672 SCHEMBL20009672 0.43 4/20
SCHEMBL20013482 SCHEMBL20013482 0.43 4/20
SCHEMBL20013173 SCHEMBL20013173 0.47 3/20
SCHEMBL22199730 SCHEMBL22199730 0.46 3/20
SCHEMBL20013155 SCHEMBL20013155 0.45 3/20
SCHEMBL22199492 SCHEMBL22199492 0.45 3/20
SCHEMBL29326814 SCHEMBL29326814 0.71 2/20
SCHEMBL25686998 SCHEMBL25686998 0.62 2/20
SCHEMBL25820476 SCHEMBL25820476 0.58 2/20
SCHEMBL25820483 SCHEMBL25820483 0.58 2/20
SCHEMBL25822037 SCHEMBL25822037 0.58 2/20
SCHEMBL25822078 SCHEMBL25822078 0.58 2/20
SCHEMBL25822086 SCHEMBL25822086 0.58 2/20
SCHEMBL25822187 SCHEMBL25822187 0.58 2/20
SCHEMBL25822048 SCHEMBL25822048 0.57 2/20
SCHEMBL25822203 SCHEMBL25822203 0.57 2/20
SCHEMBL25832693 SCHEMBL25832693 0.57 2/20

Clinical trials — most relevant to TNFRSF9 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) PHASE4COMPLETED
Simvastatin Reduces Circulating Osteoprotegerin Levels in Patients With Type 2 Diabetes PHASE4COMPLETED
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564) PHASE3COMPLETED
Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204) PHASE3COMPLETED
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease PHASE3RECRUITING
Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) PHASE2COMPLETED
Etanercept in Hidradenitis Suppurativa PHASE2COMPLETED
Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer PHASE2COMPLETED
B Cell Maturation Antigen Targeted CAR-T Cells in Treatment With Relapsed and Refractory Multiple Myeloma PHASE1/PHASE2UNKNOWN
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer PHASE2ACTIVE_NOT_RECRUITING
Trimodal Therapy Plus Atezolizumab in Muscle-invasive Bladder Cancer PHASE2UNKNOWN
Blocking Tumor Necrosis Factor in Ankylosing Spondylitis PHASE2COMPLETED
A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell Cancer PHASE2COMPLETED
Etanercept (Enbrel) to Treat Pain and Swelling After Third Molar Extraction PHASE2COMPLETED
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide PHASE2COMPLETED
Study of Etanercept and Celecoxib to Treat Temporomandibular Disorders (Painful Joint Conditions) PHASE2COMPLETED
TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma PHASE2RECRUITING
FITMI - First In Treating Male Infertility PHASE2ACTIVE_NOT_RECRUITING
Presurgical Trial of Denosumab in Breast Cancer EARLY_PHASE1COMPLETED
Evaluation of Salivary Biomarker Levels in Individuals With Different Periodontal Conditions nanCOMPLETED
Decoy Receptor 3 (DcR3) Polymorphisms in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) nanUNKNOWN
TL1A Inhibition in Systemic Sclerosis-Related Skin Fibrosis and Immunological Alterations: A Proof-of-Concept In Vitro Study (FIBROSTOP) nanNOT_YET_RECRUITING
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection nanRECRUITING
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab nanNOT_YET_RECRUITING
Correlation Between Serum Markers of Unstable Plaque and Virtual Histology of Unstable Plaque Visualized by IVUS nanCOMPLETED
Er,Cr:YSGG Laser Application in Peri-implantitis nanCOMPLETED
Using of Costimulatory and co Inhibatory Immune Checkpoints as Diagnostic and Prognostic in Breast Cancer nanUNKNOWN
Novel Biomarkers in Inflammatory Bowel Disease nanCOMPLETED
Dcr3 Levels in Blood and Urine on Renal and Patient Prognosis in Patients With Acute Kidney Injury nanUNKNOWN
Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a TNFRSF9 binder may also engage these)

ProteinNameSimilarity
P20334 — 0.985 P20334 →
P15725 — 0.982 P15725 →
Q3ZTK5 — 0.981 Q3ZTK5 →
Q28203 — 0.980 Q28203 →
P25118 — 0.977 P25118 →
P47741 — 0.977 P47741 →
A5D7R1 — 0.976 A5D7R1 →
P27512 — 0.975 P27512 →
Q3LRP1 — 0.974 Q3LRP1 →
Q7YRL5 — 0.973 Q7YRL5 →
Q8SQ34 — 0.972 Q8SQ34 →
P22934 — 0.972 P22934 →
P25446 — 0.971 P25446 →
O00300 — 0.971 O00300 →
Q8BX35 — 0.970 Q8BX35 →
Q80WY6 — 0.970 Q80WY6 →
P20333 — 0.970 P20333 →
DLK1 Protein delta homolog 1 0.969 landscape →
Q80WM9 — 0.969 Q80WM9 →
P41272 — 0.969 P41272 →
O35714 — 0.968 O35714 →
P25445 — 0.968 P25445 →
O08712 — 0.968 O08712 →
P83626 — 0.968 P83626 →
P25119 — 0.968 P25119 →
Q9BDP2 — 0.968 Q9BDP2 →
Q9HAV5 — 0.967 Q9HAV5 →
O77736 — 0.967 O77736 →
O14763 — 0.967 O14763 →
Q9BDN0 — 0.967 Q9BDN0 →